These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 7954964

  • 1. [The prognostic characteristics of hypertensive left ventricular hypertrophy in a rural population].
    Chen D, Wu K, Xie L.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Feb; 16(1):29-34. PubMed ID: 7954964
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension.
    Brown DW, Giles WH, Croft JB.
    Am Heart J; 2000 Dec; 140(6):848-56. PubMed ID: 11099987
    [Abstract] [Full Text] [Related]

  • 8. [Changes in ST segment on ECG of hypertensive patients].
    Riabykina GV, Liutikova LN, Saidova MA, Botvina IuV, Kozhemiakina ESh, Shchedrina EV, Sobolev AV.
    Ter Arkh; 2008 Dec; 80(5):67-73. PubMed ID: 18590119
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of left ventricular hypertrophy as assessed by electrocardiogram in treated hypertensive persons in general practice.
    van den Hoogen JP, van Kruijsdijk MC, van Ree JW, Mokkink HG, Thien T, van Weel C.
    J Hum Hypertens; 1993 Oct; 7(5):473-7. PubMed ID: 8263888
    [Abstract] [Full Text] [Related]

  • 10. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.
    Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E.
    J Hypertens Suppl; 1996 Dec; 14(5):S43-9. PubMed ID: 9120684
    [Abstract] [Full Text] [Related]

  • 11. [Heart rate variability in patients with hypertension and left ventricular hypertrophy].
    Stolarz K, Olszanecka A, Rajzer M, Lubaszewski W, Kawecka-Jaszcz K.
    Przegl Lek; 2002 Dec; 59(9):703-5. PubMed ID: 12632890
    [Abstract] [Full Text] [Related]

  • 12. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM, Schmieder RE.
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic implications of left ventricular hypertrophy in arterial hypertension].
    Kannel WB.
    Arch Mal Coeur Vaiss; 1990 Dec; 83 Spec No 4():11-21. PubMed ID: 2150470
    [Abstract] [Full Text] [Related]

  • 14. [Prognostic value of ventricular arrhythmia in hypertensive patients].
    Galinier M, Balanescu S, Fourcade J, Dorobantu M, Massabuau P, Dongay B, Cabrol P, Fauvel JM, Bounhoure JP.
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1049-53. PubMed ID: 9404407
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study.
    Verdecchia P, Reboldi G, Angeli F, Avanzini F, de Simone G, Pede S, Perticone F, Schillaci G, Vanuzzo D, Maggioni AP, HEART Survey Study Group.
    Am J Hypertens; 2007 Sep; 20(9):997-1004. PubMed ID: 17765142
    [Abstract] [Full Text] [Related]

  • 16. Physical activity decreases the risk of stroke in middle-age men with left ventricular hypertrophy: 40-year follow-up (1961-2001) of the Seven Countries Study (the Corfu cohort).
    Pitsavos C, Panagiotakos DB, Chrysohoou C, Kokkinos P, Menotti A, Singh S, Dontas A, Seven Countries Study (the Corfu Cohort).
    J Hum Hypertens; 2004 Jul; 18(7):495-501. PubMed ID: 14985777
    [Abstract] [Full Text] [Related]

  • 17. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 18. [QT dispersion intervals in hypertensives with left ventricular hypertrophy].
    Ghanem Wisam MA, Murín J, Jaber J, Radman A, Bulas J, Kozliková K.
    Vnitr Lek; 2001 Jan 12; 47(1):20-4. PubMed ID: 15635864
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

  • 20. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
    Palmieri V, Okin PM, de Simone G, Bella JN, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB.
    J Hypertens; 2007 May 14; 25(5):1079-85. PubMed ID: 17414673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.